In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PsiOxus Therapeutics Ltd.

www.psioxus.com

Latest From PsiOxus Therapeutics Ltd.

Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy

Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.

ImmunoOncology M & A

Transgene Hopes To Finally Catch The Wave In Virus Based Immunotherapies

Transgene's CEO discusses its immunotherapy pipeline, coming catalysts, and why the French biotech may soon be swept up by growing interest in oncolytic viruses.

Clinical Trials Companies

Appointments: Nordic Nanovector Loses CEO, Verona Pharma Loses CMO, Plus New CEOs At DalCor And PureTech Health

This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.

Appointments BioPharmaceutical

Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.

ImmunoOncology M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Transgenics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • PsiOxus Therapeutics Ltd.
  • Senior Management
  • John Beadle, MD, CEO
    Melissa Epperly, CFO
    Hilary McElwaine-Johnn, MD, CMO
    Charles Morris, Chief Dev. Officer
    Karen LaRochelle, CBO
  • Contact Info
  • PsiOxus Therapeutics Ltd.
    Phone: (44) 1235 835328
    154B Brook Dr., Milton Park
    Abingdon
    Oxfordshire, OX14 4SD
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register